- CAR T cell therapy has shown promise in treating severe autoimmune diseases, including systemic lupus erythematosus, by inducing long-term remission.
- 17 out of 18 patients with SLE achieved sustained remission after a single infusion of engineered T cells in a landmark study.
- Most patients were able to discontinue all immunosuppressive medications, often for the first time in over a decade.
- CAR T therapy may offer a potential cure for autoimmune disorders, rather than lifelong symptom management.
- The therapy modifies a patient’s own immune cells to target malfunctioning immune systems, rather than broadly suppressing immune activity.
In a medical breakthrough blurring the lines between oncology and immunology, CAR T cell therapy—originally designed to combat blood cancers—has induced long-term remission in patients with severe autoimmune diseases who had exhausted all other treatment options. In a landmark study published in Nature Medicine, 17 out of 18 patients with systemic lupus erythematosus (SLE), a debilitating autoimmune condition, achieved sustained remission after a single infusion of engineered T cells. Remarkably, most patients were able to discontinue all immunosuppressive medications, some for the first time in over a decade. This unprecedented success suggests that CAR T therapy, which modifies a patient’s own immune cells to target cancer, might also be repurposed to ‘reset’ malfunctioning immune systems, offering a potential cure rather than lifelong symptom management for millions affected by autoimmune disorders worldwide.
The Immune System’s Double-Edged Sword
Autoimmune diseases occur when the immune system mistakenly attacks the body’s own tissues, leading to chronic inflammation and organ damage. Conditions like lupus, multiple sclerosis, and rheumatoid arthritis affect more than 8% of the global population, with limited treatment options centered on broadly suppressing immune activity—often at the cost of increased infection risk and long-term organ toxicity. Traditional therapies rarely induce remission and typically require lifelong administration. Now, researchers are reimagining CAR T therapy not as a cancer-only tool, but as a precision strike against overactive immune cells. Unlike conventional immunosuppressants, CAR T cells can selectively eliminate the rogue B cells responsible for autoimmune attacks, potentially erasing the disease’s root cause. With autoimmune disorders ranking among the top 10 causes of death in women under 65, this shift could redefine treatment standards if proven safe and scalable.
From Blood Cancers to Autoimmune Revolutions
Chimeric antigen receptor (CAR) T cell therapy was first approved by the FDA in 2017 for certain types of lymphoma and leukemia. The treatment involves extracting a patient’s T cells, genetically engineering them to recognize specific proteins on cancer cells—typically CD19 on B cells—and reinfusing them to hunt down and destroy malignant cells. Now, clinical teams in Germany, the U.S., and the U.K. are applying the same approach to autoimmune diseases, targeting the same CD19 marker on pathogenic B cells that drive conditions like lupus and myasthenia gravis. In a 2023 trial at University Hospital Frankfurt, all nine lupus patients treated with CD19-directed CAR T therapy went into remission within three months, with benefits lasting over 18 months. Similar results were observed in patients with anti-MAG neuropathy and systemic sclerosis, suggesting the approach may have broad applicability across B cell-mediated autoimmune conditions.
Why This Therapy Could Reshape Immunology
The success of CAR T in autoimmune disease hinges on its ability to induce deep, lasting remission by eliminating disease-causing immune cells while allowing the immune system to regenerate from stem cells in the bone marrow. This ‘immune reset’ contrasts sharply with existing treatments that merely dampen immune responses. Experts believe the therapy works because, after CAR T infusion, the immune system rebuilds without the autoreactive B cell clones that trigger disease. Dr. Georg Schett, lead researcher on the lupus trial, noted that ‘the immune system returns to a pre-autoimmune state, like rebooting a malfunctioning computer.’ Data from early trials show normalization of kidney function in lupus patients and reduced autoantibody levels across multiple conditions. However, concerns remain about long-term risks, including infection due to prolonged B cell depletion and the high cost—currently over $400,000 per treatment—which may limit access despite its transformative potential.
Who Stands to Gain—and What’s at Stake
If future trials confirm safety and efficacy, CAR T therapy could offer a functional cure for severe autoimmune patients who face decades of disability and medication side effects. The implications extend beyond individual health: reducing hospitalizations, chronic care needs, and lost productivity could significantly lower healthcare costs over time. However, the treatment is not without risks. Some patients experience cytokine release syndrome, a potentially life-threatening inflammatory response, and long-term B cell suppression may increase vulnerability to infections. For now, CAR T remains reserved for the most severe, treatment-resistant cases. Still, pharmaceutical companies including Novartis and BMS are fast-tracking autoimmune CAR T development, with phase II trials underway. The real challenge will be making the therapy scalable and affordable, possibly through off-the-shelf allogeneic versions currently in research pipelines.
Expert Perspectives
Opinions are divided on how quickly CAR T should expand into autoimmune care. Dr. David Rawlings of Seattle Children’s Research Institute calls it ‘the most significant advance in immunology in decades,’ arguing that the depth of remission justifies the risks in refractory cases. Others urge caution: Dr. Virginia Pascual, an immunologist at Weill Cornell Medicine, warns that ‘we don’t yet understand which patients will sustain remission or whether disease might re-emerge years later.’ She advocates for biomarker development to predict response and long-term monitoring. Meanwhile, bioethicists are raising concerns about equitable access, given the therapy’s cost and complexity. The consensus is clear: while not a panacea, CAR T represents a paradigm shift in how we treat autoimmune disease—not as a chronic burden, but as a potentially curable condition.
Looking ahead, the next five years will be critical. Larger, randomized trials are needed to confirm efficacy across diverse autoimmune conditions and patient populations. Researchers are also exploring lower-intensity conditioning regimens to reduce side effects and investigating whether earlier intervention—before organ damage occurs—could maximize benefits. If successful, CAR T could move from last resort to first-line curative therapy for select autoimmune diseases. The question is no longer if, but when and how widely this revolutionary approach will transform medicine beyond oncology.
Source: Ars Technica